摘要
目的:探讨血清胆碱酯酶和腺苷脱氨酶联合检测在诊断肝硬化不同病程分期的临床意义。方法:选择20例失代偿期肝硬化患者分为失代偿组,随机选取20例代偿期肝硬化患者和20例健康人群分别分为代偿组和健康组,对3组人群的血清胆碱酯酶和腺苷脱氨酶活性进行检测并比较其差异。结果:代偿组和失代偿组的CHE活性均要显著低于健康组,差异有统计学意义(t=8.34,P<0.01、t=12.03,P<0.01),失代偿组要显著低于代偿组,差异有统计学意义(t=4.07,P<0.01);代偿组和失代偿组ADA活性均要显著高于健康组,差异有统计学意义(t=11.19,P<0.01、t=17.07,P<0.01),失代偿组要显著高于代偿组,差异有统计学意义(t=7.38,P<0.01)。结论:血清胆碱酯酶和腺苷脱氨酶活性随着肝硬化病程发展发生显著变化,其联合检测可以为病程发展的临床诊断提供一定的依据。
Objective： To investigate the clinical significance in diagnosing different stages of cirrhosis by combining detection serum cholinesterase and adenosine deaminase. Methods： 20 cases of patients with decompensated cirrhosis were divided into decompensation group, randomly selected 20 cases of compensated cirrhosis patients and 20 healthy subjects were divided into compensatory group and healthy group, detected 3 groups serum cholinesterase, serum adenosine deaminase activity and compared the differences. Results： Compensation group and decompensated group CHE activity were to be significantly lower than the healthy group, decompensated group was significantly lower than the compensatory group, compensation group and decompensated group ADA activity were to be significantly higher than the healthy group, decompensated group was significantly higher than compensatory group. Conclusions： Serum cholinesterase and adenosine deaminase activity with the progression of cirrhosis significant change, the combined detection could be provide a basis for progression of clinical diagnosis.
出处
《现代生物医学进展》
CAS
2014年第8期1494-1496,共3页
Progress in Modern Biomedicine
基金
国家自然科学基金项目(81170397)
关键词
胆碱酯酶
腺苷脱氨酶
肝硬化
临床分型
Cholinesterase
Adenosine deaminase
Cirrhosis
Clinical type
